Additional Phase 3 Data Supporting OPKO's Rayaldee as a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at Kidney Week 2015

OPKO Health, Inc. OPK, a multinational biopharmaceutical and diagnostics company, announces that additional Phase 3 data on Rayaldee™ as a treatment for secondary hyperparathyroidism (SHPT) will be highlighted later today in a poster presentation at Kidney Week 2015, the Annual Meeting of the American Society of Nephrology (ASN) underway in San Diego, California. The data showed that plasma levels of intact parathyroid hormone (iPTH) continued to fall as serum levels of 25-hydroxyvitamin D (25D) rose above 30 ng/mL, a level considered sufficient for CKD patients in published clinical practice guidelines. These data suggest that patients with stage 3 or 4 CKD require higher levels of serum 25D than previously thought in order to control elevated iPTH. OPKO's poster presentation entitled "Efficacy and Safety of Modified-Release Calcifediol in Stage 3-4 CKD Patients with Secondary Hyperparathyroidism and Vitamin D Insufficiency," will be presented by lead author Stuart M. Sprague, DO, Chief, Division of Nephrology and Hypertension, NorthShore University Health System - University of Chicago, Pritzker School of Medicine.